

SECURITIES AND EXCHANGE COMMISSION

FORM 15-12G

Notice of termination of registration of a class of securities under Section 12(g)

Filing Date: **2013-01-11**
SEC Accession No. [0001104659-13-002071](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

ANGIOTECH PHARMACEUTICALS INC

CIK: [1096481](#) | IRS No.: **000000000** | Fiscal Year End: **1231**
Type: **15-12G** | Act: **34** | File No.: [000-30334](#) | Film No.: **13525522**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address
*1618 STATION STREET
VANCOUVER A1 V6A 1B6*

Business Address
*1618 STATION STREET
VANCOUVER A1 V6A 1B6
604-221-7676*

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 15

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number **000-30334**

Angiotech Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

355 Burrard St., Suite 1100, Vancouver, BC V6C 2G8, Canada

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

OLD COMMON Shares, Without Par Value

(Title of each class of securities covered by this Form)

n/a

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input checked="" type="checkbox"/>

Approximate number of holders of record as of the certification or notice date: 0

Pursuant to the requirements of the Securities Exchange Act of 1934 Angiotech Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: January 11, 2013

By: /s/ K. Thomas Bailey

Name: K. Thomas Bailey

Title: President and Chief Executive Officer

Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be

signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.
